BioFocus has announced that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.
Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.
“We are delighted to have the opportunity to support The Michael J. Fox Foundation in its development of improved therapies for those living with Parkinson’s,” said Dr Kate Hilyard, VP Biological Sciences.
Dr Hilyard continued, “The collaboration will utilize BioFocus' biology platform that delivers drug discovery solutions through its experienced teams and state-of-the-art technologies”.